Literature DB >> 24498972

Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.

Nathalie Rock1, V Mattiello, C Judas, P Huezo-Diaz, J P Bourquin, F Gumy-Pause, M Ansari.   

Abstract

In adult therapy, arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) are recognized as active treatment of relapsed acute promyelocytic leukemia (APL). The efficacy of this combination in pediatric APL has not yet been well established. We report the case of a 6-year-old girl with relapsed APL, with a PML-RARα mutation, treated with a combination of ATO and ATRA. Over a period of 5 months, she received in total, 75 doses of intravenous ATO and 40 doses of oral ATRA. Currently, 22 months after relapse, she is still in complete remission. Here, we describe treatment of a relapsed APL in a child with limited treatment of ATO and ATRA and review the literature.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24498972     DOI: 10.3109/08880018.2013.876470

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  2 in total

1.  ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.

Authors:  Zi-Jie Long; Yuan Hu; Xu-Dong Li; Yi He; Ruo-Zhi Xiao; Zhi-Gang Fang; Dong-Ning Wang; Jia-Jun Liu; Jin-Song Yan; Ren-Wei Huang; Dong-Jun Lin; Quentin Liu
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

2.  Endothelial to mesenchymal transition contributes to arsenic-trioxide-induced cardiac fibrosis.

Authors:  Yong Zhang; Xianxian Wu; Yang Li; Haiying Zhang; Zhange Li; Ying Zhang; Longyin Zhang; Jiaming Ju; Xin Liu; Xiaohui Chen; Peter V Glybochko; Vladimir Nikolenko; Philipp Kopylov; Chaoqian Xu; Baofeng Yang
Journal:  Sci Rep       Date:  2016-09-27       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.